Oncology Institute Q3 revenue jumps, partly on organic growth in Florida, Oregon
Oncology Institute's Q3 revenue increased by 36.7% year-over-year, driven by organic growth in Florida and Oregon. The net loss widened slightly to $16.5 million. The company updated its full-year revenue guidance to $495-$505 million and revised its Adjusted EBITDA guidance. Fee-for-service revenue grew 13%, and pharmacy records contributed significantly. Analysts rate the shares as "buy," with a median price target of $7.00, 51% above the current price.
)
Overview
- Oncology Institute Q3 revenue rises 36.7% yr/yr, driven by organic growth in Florida, Oregon
- Net loss for Q3 widens slightly to $16.5 mln compared to $16.1 mln last year
- The cancer clinics operator updates full-year revenue guidance to $495-$505 mln
Outlook
- Company updates full-year revenue guidance to $495 mln-$505 mln, from prior outlook of $460-$480 mln
- Company revises full-year Adjusted EBITDA guidance to $(11) mln-$(13) mln
- Company expects Q4 Adjusted EBITDA of $0 to $2 mln
Result Drivers
- ORGANIC GROWTH - Fee-for-service revenue grew 13% over Q3 2024, driven by organic growth in Florida and Oregon
- PHARMACY RECORDS - Retail Pharmacy and Dispensary set fill records, contributing $75.9 mln in revenue and $12.8 mln in gross profit
- NEW PROVIDERS - Signed several new in-network MSO providers in Florida and opened a new pharmacy location
Key Details
Metric Beat/Mis Actual Consensu
s s
Estimate
Q3 EPS -$0.14
Q3 Net -$16.50
Income mln
Q3 Gross $18.90
Profit mln
Analyst Coverage
- The current average analyst rating on the shares is “buy” and the breakdown of recommendations is 3 “strong buy” or “buy”, no “hold” and no “sell” or “strong sell”
- The average consensus recommendation for the healthcare facilities & services peer group is “buy”
- Wall Street’s median 12-month price target for Oncology Institute Inc is $7.00, about 51% above its November 12 closing price of $3.43
Press Release: For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact . (This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)
